Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Change in Cash (2016 - 2025)

Historic Change in Cash for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to $91.4 million.

  • Ascendis Pharma A's Change in Cash rose 19779.66% to $91.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $99.2 million, marking a year-over-year decrease of 3937.17%. This contributed to the annual value of $92.4 million for FY2025, which is 4022.13% down from last year.
  • As of Q4 2025, Ascendis Pharma A's Change in Cash stood at $91.4 million, which was up 19779.66% from $47.9 million recorded in Q3 2025.
  • Ascendis Pharma A's Change in Cash's 5-year high stood at $407.7 million during Q3 2024, with a 5-year trough of -$292.7 million in Q4 2021.
  • Its 5-year average for Change in Cash is -$230787.0, with a median of -$56.5 million in 2023.
  • The largest annual percentage gain for Ascendis Pharma A's Change in Cash in the last 5 years was 81662.5% (2024), contrasted with its biggest fall of 22229.88% (2024).
  • Ascendis Pharma A's Change in Cash (Quarter) stood at -$292.7 million in 2021, then surged by 50.81% to -$144.0 million in 2022, then skyrocketed by 68.71% to -$45.1 million in 2023, then crashed by 107.47% to -$93.5 million in 2024, then skyrocketed by 197.8% to $91.4 million in 2025.
  • Its Change in Cash was $91.4 million in Q4 2025, compared to $47.9 million in Q3 2025 and -$5.3 million in Q2 2025.